TY - JOUR
T1 - Treatment of COVID-19
T2 - Perspective on Convalescent Plasma Transfusion
AU - Farhat, Ryan M.
AU - Mousa, Mohammad A.
AU - Daas, Eshaan J.
AU - Glassberg, Marilyn K.
N1 - Publisher Copyright:
© Copyright © 2020 Farhat, Mousa, Daas and Glassberg.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/7/28
Y1 - 2020/7/28
N2 - The novel coronavirus (COVID-19) has continued its global spread since the first documented case in late 2019 in Wuhan, China. With over 10 million cases and 500 thousand deaths reported worldwide, the need for an effective treatment regimen is evident. Historically, convalescent plasma (CP) has been utilized in the treatment of viral respiratory pathogens. Critically ill patients with COVID-19 in China and South Korea have been treated with CP given the ineffectiveness of experimental therapies with antivirals alone. This commentary explores the importance of published experience and the pending establishment of efficacy to facilitate an informed decision regarding the therapeutic use of CP. With increasing mortality around the world from COVID-19 infection, the need for alternative, effective treatment regimens is critical.
AB - The novel coronavirus (COVID-19) has continued its global spread since the first documented case in late 2019 in Wuhan, China. With over 10 million cases and 500 thousand deaths reported worldwide, the need for an effective treatment regimen is evident. Historically, convalescent plasma (CP) has been utilized in the treatment of viral respiratory pathogens. Critically ill patients with COVID-19 in China and South Korea have been treated with CP given the ineffectiveness of experimental therapies with antivirals alone. This commentary explores the importance of published experience and the pending establishment of efficacy to facilitate an informed decision regarding the therapeutic use of CP. With increasing mortality around the world from COVID-19 infection, the need for alternative, effective treatment regimens is critical.
KW - SARS–CoV-2
KW - convalescent plasma for COVID-19 therapy
KW - coronavirus (2019-nCoV)
KW - neutralizing antibody titers (NAT)
KW - transfusion safety
UR - http://www.scopus.com/inward/record.url?scp=85089502239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089502239&partnerID=8YFLogxK
U2 - 10.3389/fmed.2020.00435
DO - 10.3389/fmed.2020.00435
M3 - Article
AN - SCOPUS:85089502239
VL - 7
JO - Frontiers in Medicine
JF - Frontiers in Medicine
SN - 2296-858X
M1 - 435
ER -